A detailed history of Jefferies Group LLC transactions in Jounce Therapeutics, Inc. stock. As of the latest transaction made, Jefferies Group LLC holds 132,115 shares of JNCE stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares
132,115
Holding current value
$0
% of portfolio
0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

BUY
$2.73 - $4.92 $360,673 - $650,005
132,115 New
132,115 $309,000
Q4 2019

Feb 13, 2020

SELL
$2.81 - $9.21 $38,095 - $124,859
-13,557 Closed
0 $0
Q3 2019

Nov 13, 2019

BUY
$3.33 - $4.93 $45,144 - $66,836
13,557 New
13,557 $45,000

Others Institutions Holding JNCE

About Jounce Therapeutics, Inc.


  • Ticker JNCE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 51,694,200
  • Description
  • Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...
More about JNCE
Track This Portfolio

Track Jefferies Group LLC Portfolio

Follow Jefferies Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jefferies Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jefferies Group LLC with notifications on news.